Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing
BRAF inhibitor
Erdheim-Chester disease
cerebellar syndrome
histiocytosis
interferon
psychosis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
05
2022
accepted:
08
06
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
27
7
2022
Statut:
epublish
Résumé
Erdheim-Chester disease (ECD) is a rare condition with underestimated neurological involvement. Mild psychiatric symptoms such as mood swings have been rarely described in the clinical spectrum of neuro-ECD. We here describe the first patient with psychiatric manifestations of delirium revealing ECD with neurological involvement with favorable evolution under interferon followed by BRAF inhibitor monotherapy. An 81-year-old woman was referred to the hospital because of delirium and severe cognitive impairment associated with a cerebellar syndrome. Brain magnetic resonance imaging showed "FLAIR-changes" lesions in the pons and upper cerebellum peduncles. Blood and cerebrospinal fluid (CSF) analyses showed normal results except for an elevated neopterin level in the CSF. Whole-body CT scan (
Identifiants
pubmed: 35874752
doi: 10.3389/fimmu.2022.918613
pmc: PMC9299438
doi:
Substances chimiques
Antiviral Agents
0
Protein Kinase Inhibitors
0
Vemurafenib
207SMY3FQT
Interferons
9008-11-1
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
918613Informations de copyright
Copyright © 2022 Razanamahery, Abdallahoui, Chabridon, Fromont, Tarris, Idbaih, Comby, Godard, Haroche, Audia and Bonnotte.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Orphanet J Rare Dis. 2016 Aug 02;11(1):109
pubmed: 27484739
Neuro Oncol. 2020 Jul 7;22(7):979-992
pubmed: 31950179
Cancer Discov. 2016 Feb;6(2):154-65
pubmed: 26566875
Neuro Oncol. 2021 Sep 1;23(9):1433-1446
pubmed: 33993305
Blood Adv. 2019 Apr 9;3(7):934-938
pubmed: 30917949
Orphanet J Rare Dis. 2022 Mar 2;17(1):92
pubmed: 35236371
Am J Hematol. 2018 May;93(5):E114-E117
pubmed: 29396850
Neurology. 2020 Nov 17;95(20):e2746-e2754
pubmed: 32887776
Blood. 2020 May 28;135(22):1929-1945
pubmed: 32187362
Cancer. 2018 Jun 15;124(12):2607-2620
pubmed: 29624648
Aust N Z J Psychiatry. 2019 Mar;53(3):219-227
pubmed: 30369245
Lancet Neurol. 2017 Dec;16(12):953-954
pubmed: 29111143
Clin Vaccine Immunol. 2011 Apr;18(4):609-14
pubmed: 21270283
CNS Spectr. 2020 Jun;25(3):402-408
pubmed: 31130152
J Psychiatr Res. 2015 Dec;71:134-9
pubmed: 26476490
Sci Rep. 2020 Oct 26;10(1):18291
pubmed: 33106568
Nature. 2017 Sep 21;549(7672):389-393
pubmed: 28854169
J Neuropsychiatry Clin Neurosci. 2004 Summer;16(3):367-78
pubmed: 15377747
Blood. 2018 Jun 28;131(26):2877-2890
pubmed: 29720485
Blood. 2017 Sep 14;130(11):1377-1380
pubmed: 28667012
Ann Clin Transl Neurol. 2020 Apr;7(4):497-506
pubmed: 32227455
Neurochem Int. 1999 Jun;34(6):523-30
pubmed: 10402228
JAMA Neurol. 2020 Nov 1;77(11):1446-1447
pubmed: 32716494